Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) GlobeNewswire August 05, 2025 With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile BEAM-302 Expanded […]

First Watch Restaurant Group, Inc. Reports Q2 2025 Financial Results and Reaches 600th System-Wide Restaurant Milestone

First Watch Restaurant Group, Inc. Reports Q2 2025 Financial Results and Reaches 600th System-Wide Restaurant Milestone GlobeNewswire August 05, 2025 Total revenues increased 19.1%Net income of $2.1 million and Adjusted EBITDA of $30.4 million17 new system-wide restaurants opened in 8 statesRaising 2025 Adjusted EBITDA guidance BRADENTON, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) — First Watch

PyroGenesis Signs Additional Contract with Constellium to Advance Aluminum Furnace Electrification Using Plasma Torch Technology

PyroGenesis Signs Additional Contract with Constellium to Advance Aluminum Furnace Electrification Using Plasma Torch Technology Marks next phase of industrial-scale deployment for aluminum sector energy transition. GlobeNewswire August 05, 2025 MONTREAL, Aug. 05, 2025 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a high-tech company that designs, develops, manufactures and

GlobalFoundries Reports Second Quarter 2025 Financial Results

GlobalFoundries Reports Second Quarter 2025 Financial Results GlobeNewswire August 05, 2025 MALTA, N.Y., Aug. 05, 2025 (GLOBE NEWSWIRE) — GLOBALFOUNDRIES Inc. (GF) (Nasdaq: GFS) today announced preliminary financial results for the second quarter ended June 30, 2025. Key Second Quarter Financial Highlights Revenue of $1.688 billion Gross margin of 24.2% and Non-IFRS gross margin(1) of

Ontario Media Advisory: MADD Canada and its Local Chapter MADD Windsor & Essex County to Unveil Memorial Garden in Honour of Victims and Survivors of Crashes Involving Alcohol and/or Drugs

Ontario Media Advisory: MADD Canada and its Local Chapter MADD Windsor & Essex County to Unveil Memorial Garden in Honour of Victims and Survivors of Crashes Involving Alcohol and/or Drugs GlobeNewswire August 05, 2025 WINDSOR, Ontario, Aug. 05, 2025 (GLOBE NEWSWIRE) — MADD Canada and its local Chapter MADD Windsor & Essex County will host

Enviri Corporation Reports Second Quarter 2025 Results

Enviri Corporation Reports Second Quarter 2025 Results GlobeNewswire August 05, 2025 Second quarter revenues totaled $562 million Second quarter GAAP consolidated loss from continuing operations of $46 million Adjusted EBITDA in Q2 totaled $65 million 2025 Adjusted EBITDA now expected to be within a range of $290 million to $310 million and free cash flow

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights GlobeNewswire August 05, 2025 – First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5 inhibitor in development for glioblastoma – BOSTON, Aug. 05, 2025

Bitfarms Announces Partnership with T5 Data Centers to Advance HPC/AI Development at Panther Creek Campus

Bitfarms Announces Partnership with T5 Data Centers to Advance HPC/AI Development at Panther Creek Campus GlobeNewswire August 05, 2025 TORONTO, Ontario and NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) — Bitfarms Ltd. (Nasdaq/TSX: BITF) (the “Company”), a global energy and compute infrastructure company, today announced its partnership with T5 Data Centers, LLC (“T5”) to advance

Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update

Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update GlobeNewswire August 05, 2025 FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track Preclinical synergistic benefit of FHD-909 in combination with pembrolizumab and KRAS

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference GlobeNewswire August 05, 2025 SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a fireside chat at the

Scroll to Top